CoChat

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Open access

Abstract

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin-angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV complications remain. Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight. In the kidney, increased sodium delivery to the macula densa mediated by SGLT-2 inhibition has the potential to reduce intraglomerular pressure, which may explain why SGLT-2 inhibitors reduce albuminuria and appear to slow kidney function decline in people with diabetes. Importantly, in the trials completed to date, these benefits appeared to be maintained at lower levels of kidney function, despite attenuation of glycosuric effects, and did not appear to be dependent on ambient hyperglycaemia. There is therefore a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration (i.e. those with substantially reduced nephron mass and/or albuminuria), irrespective of whether they have diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ckj/sfy090

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Mechanistic concept of the effects of RAS and SGLT-2 inhibition on intraglomerular pressure.
FIGURE 1 Mechanistic concept of the effects of RAS and SGLT-2 inhibition on intraglomerular pressure.CC BY · PubMed Central
FIGURE 2 Effect of allocation to empagliflozin versus placebo on Chronic Kidney Disease Epidemiology Collaboration eGFR.
FIGURE 2 Effect of allocation to empagliflozin versus placebo on Chronic Kidney Disease Epidemiology Collaboration eGFR.CC BY · PubMed Central
FIGURE 3 Effect of allocation to empagliflozin versus placebo on (A) traditional kidney disease progression outcome (post hoc) and (B) incident or worsening nephropathy, by baseline eGFR and uACR.
FIGURE 3 Effect of allocation to empagliflozin versus placebo on (A) traditional kidney disease progression outcome (post hoc) and (B) incident or worsening nephropathy, by baseline eGFR and uACR.CC BY · PubMed Central
FIGURE 4 Effect of allocation to empagliflozin versus placebo on (A) CV death, (B) CV death or hospitalization for HF and (C) all-cause hospitalization, by baseline eGFR.
FIGURE 4 Effect of allocation to empagliflozin versus placebo on (A) CV death, (B) CV death or hospitalization for HF and (C) all-cause hospitalization, by baseline eGFR.CC BY · PubMed Central
FIGURE 5 Effect of allocation to empagliflozin versus placebo on adverse events, by baseline eGFR.
FIGURE 5 Effect of allocation to empagliflozin versus placebo on adverse events, by baseline eGFR.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 1

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Guideline Development Work Group, 2013, KDIGO clinical practice guideline for lipid management in chronic kidney disease, Kidney Int Suppl, 3, 263

Cited by

See all 237

Metadata

Authors
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., & Wanner, C.
Affiliations
  • University of Oxford (GB)
  • Boehringer Ingelheim (Germany) (DE)
  • Duke Medical Center (US)
  • Universitätsklinikum Würzburg (DE)
Corresponding author
Herrington, William G
Venue
Clinical Kidney Journal
Published
2018-10-25
Volume
11
Issue
6
Pages
749-761
ISSN
  • 2048-8505 (ISSN-L)
  • 2048-8513
OpenAlex
W2898388822
Cited by
237
References
79
Citations by year
2026: 5 · 2025: 9 · 2024: 8 · 2023: 23 · 2022: 49 · 2021: 64 · 2020: 48 · 2019: 29 · 2018: 1
FWCI
6.09
Type
journal article
Language
en
Open access
Locations
  • Clinical Kidney Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Medical Research Council
  • Kidney Research UK
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
SGLT2 inhibitors, chronic kidney disease, EMPA-KIDNEY trial, cardiovascular outcomes, albuminuria, hyperfiltration, intraglomerular pressure, renal function decline, non-diabetic chronic kidney disease, renin-angiotensin system, heart failure hospitalization, cardiovascular mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. https://app.cochat.ai/papers/10.1093/ckj/sfy090
The paper
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., & Wanner, C. (2018). The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfy090

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.